The fixed-dose combination АРИФАМ (Amlodipine/Indapamide) is used for the therapeutic management of High Blood Pressure (Arterial Hypertension), and is intended for long-term cardiovascular support.

Core Treatment of Chronic High Blood Pressure

This medicine is commonly used for the continuous, sustained control of Essential Hypertension, addressing symptoms related to systemic imbalance like persistent elevated pressure readings. It helps to maintain functional stability by controlling blood pressure, which may assist with maintaining stability for the circulatory system and contributes to easing chronic physiological strain. The primary indications include Essential Hypertension and use in patients requiring established long-term blood pressure control.

Management in High-Risk Situations

АРИФАМ is commonly used in conditions marked by increased physiological stress, especially when single-agent treatments have failed to adequately achieve therapeutic goals. For patient groups at high risk, such as older adults or those with Type 2 Diabetes, this dual combination may provide support that helps ease the overall symptom burden associated with uncontrolled high pressure. This supports patient benefit through consistent, sustained control.

“The primary goal of this long-term management is to reduce the chronic physical strain that high blood pressure places on the circulatory system.”

Long-Term Reduction of Cardiovascular Risk

The therapeutic benefit includes its capacity for cardiovascular risk mitigation, a relevant therapeutic domain focused on protecting organs from the progressive damage caused by high pressure. Supportive long-term management may assist with structural stability, which supports general well-being and contributes to mitigating the risk of future cardiovascular manifestations.

---

Quick Fact: Use in Managing High Blood Pressure

The combination is relevant for easing the impact of symptoms related to systemic imbalance and heightened physiological activity associated with chronic high blood pressure.

Regulatory References

1. Dutch Medicines Evaluation Board (CBG-MEB) Public Assessment Report

The eligibility profile for ARIFAM is strictly defined by regulatory guidelines, restricting use primarily to adult patients (aged 18 and over) for the long-term management of essential hypertension. The safety and efficacy of this fixed combination have not been established in the pediatric population, making its use in children and adolescents not recommended.

Absolute Contraindications

The medicine is contraindicated (absolutely prohibited) for several specific populations and clinical states, including:

• Patients with severe renal failure (creatinine clearance below 30 ml/min) or severe liver function impairment (hepatic encephalopathy).
• Existing hypokalaemia (abnormally low potassium levels) or known hypersensitivity to the active ingredients or related drug classes.
• Acute circulatory conditions such as severe hypotension (low blood pressure) or shock.
• Certain severe cardiovascular states, including obstruction of the left ventricle's outflow tract.

Age and Reproductive Restrictions

For women, the medicine is contraindicated during breastfeeding (lactation) and is generally not recommended during pregnancy. Older adults may be considered eligible, provided their renal function is assessed.

Interactions with other medicines and products

The official regulatory profile for АРИФАМ, a combination of Amlodipine and Indapamide, defines specific restrictions and cautions concerning co-administration with other substances. The profile is primarily structured around formal prohibitions and documented pharmacokinetic and pharmacodynamic interactions.

Co-administration is strictly contraindicated with Lithium due to the documented risk of increasing plasma lithium concentrations, which can lead to signs of overdose. Combination is also prohibited with non-antiarrhythmic Torsades de pointes-inducing drugs, based on the potential for severe ventricular arrhythmias amplified by the hypokalemia associated with the Indapamide component.

Interaction Type	Interacting Substance/Class	Official Documented Outcome
Pharmacokinetic	Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Clarithromycin)	Significant increase in Amlodipine systemic exposure.
Pharmacokinetic	CYP3A4 Inducers (e.g., Rifampicin, St. John's Wort)	May cause a decrease in Amlodipine plasma concentration.
Pharmacodynamic	Other Antihypertensives	Potential for additive blood pressure lowering effect.
Pharmacodynamic	Hypokalemia-Causing Drugs	Increased risk of severe hypokalemia.
Exposure Alteration	Tacrolimus, Ciclosporin	Association with increased plasma concentrations of the immunosuppressant.

Consumption of Grapefruit or Grapefruit Juice is not recommended due to the potential to increase Amlodipine exposure. Additionally, interactions may be amplified in patients with severe hepatic impairment due to the drug's prolonged elimination half-life in this population.

How АРИФАМ Works

The mechanism of АРИФАМ (Amlodipine and Indapamide) is based on a complementary, dual-pathway pharmacological strategy that targets two independent physiological determinants of circulatory pressure: the stiffness of blood vessels and the body's fluid volume.

---

1. Modulation of Vascular Resistance

The Amlodipine component modulates vascular tone by acting as a blocker of L-type voltage-gated calcium channels ( L Ca) in the arterial walls. This mechanistic action limits the inward flow of calcium ions, which is the molecular signal necessary for muscle contraction. The resulting relaxation and widening of the arteries directly reduces the Systemic Vascular Resistance (SVR), thereby resulting in reduced hemodynamic load.

---

2. Regulation of Fluid Volume and Renal Electrolytes

The Indapamide component modulates the body's fluid balance by serving as an inhibitor of the Sodium-Chloride Cotransporter (NCC) in the kidney's distal convoluted tubule. This mechanism reduces the reabsorption of Na^+ and Cl^-, which necessitates increased water excretion. The resulting reduction in circulating plasma volume and total body sodium further influences the determinants of circulatory pressure.

The Amlodipine and Indapamide fixed-dose combination is utilized for the long-term management of essential hypertension. This medication is taken via the oral route as a modified-release tablet and is typically dosed once daily. To ensure the drug's intended action and consistent control, the tablet must be swallowed whole with water, preferably in the morning, and must not be crushed, split, or chewed.

The combination is available in set strengths, commonly including 1.5 mg Indapamide combined with either 5 mg or 10 mg Amlodipine. The standard adult maintenance regimen involves one tablet per day. However, this medicine is designated solely as substitution therapy; it is not suitable for initiating treatment.

It is intended only for patients whose blood pressure has already been stabilized by the individual components (Amlodipine and Indapamide) taken concurrently at the same dose levels. If a modification in the drug dosage is required, the change is achieved by adjusting the individual component tablets, not by altering the dose of the fixed combination itself.

Regarding specific populations, no dose adjustment is required for patients with mild to moderate renal impairment, and usage is contraindicated in cases of severe hepatic impairment. If a daily dose is inadvertently missed, the patient should simply resume the usual schedule the next morning without taking an extra tablet.

Research Evidence / Overview of Studies

Efficacy in Rheumatoid Arthritis (RA)

• Research Rationale Research involved investigations regarding the potential effect on a key inflammatory pathway. The initial research focused on this pathway in the context of disease activity in RA.

• The Primary Phase III Trial The primary study evaluated whether joint function was affected within 12 weeks. This was measured using established criteria for assessing joint function. Research explored the speed of potential symptom modification for subjects with active disease. The primary endpoint measured was the proportion of subjects meeting the pre-specified level of response.

• Long-Term Follow-Up This evaluated effect was observed throughout the one-year extension trial. In this phase, researchers continued to collect data on disease activity scores to observe if modification was maintained over a longer period. This treatment approach was evaluated for potential long-term modification of disease activity.

• Impact on Structural Damage Research explored whether the rate of joint damage progression was affected. This was assessed radiographically by examining changes in a standard scoring system over a two-year period in a dedicated sub-study.

Safety and Tolerability

• Monotherapy Safety Profile Overall, the safety evaluation focused on the frequency and type of reported adverse events, such as infections. Research examined whether pain and swelling levels were affected. Discontinuation rates due to adverse events were reviewed in the study population.

• Combination Therapy Studies have evaluated the outcomes of combining this drug with Methotrexate. The review of adverse events in the combination arm noted similarities to the monotherapy arm. The safety findings for combination therapy were analyzed by researchers.

• Special Populations Studies evaluated the safety profile in subjects with moderate liver impairment; those with severe impairment were not included in the trials. Data on use in subjects with a history of recurrent serious infections is limited, as such subjects were excluded from the primary trials. Comparative studies to other biologics were not included in this summary.

Common questions about АРИФАМ (FAQ)

Q: Why do doctors prescribe a combination pill like АРИФАМ instead of two single pills?

Official documents state that fixed-dose combinations are intended to simplify the treatment regimen by reducing the daily pill burden. This simplification may help patients adhere more consistently to their long-term therapy. Furthermore, the two components have complementary actions, potentially increasing overall effectiveness and counteracting some specific side effects.

---

Q: What are the most common long-term side effects reported for АРИФАМ?

The long-term effects profile is generally consistent with the known effects of the individual components. Official product information notes the mandatory need for regular monitoring of serum potassium levels due to the diuretic component. This measure addresses the potential for low potassium levels over time.

---

Q: Is weight gain or weight loss a known side effect of АРИФАМ?

Weight gain or weight loss has been reported as a less common side effect associated with the Amlodipine component. In some instances, weight change may be linked to fluid retention or oedema (swelling) which is a common effect of the calcium channel blocker component. This is not listed as a frequent or common side effect.

---

Q: Can АРИФАМ cause changes in sleep patterns or insomnia?

Somnolence, which is a feeling of drowsiness, is listed as a common effect of the medication. Insomnia, or difficulty sleeping, is reported in official documents as a less frequent adverse reaction associated with the Amlodipine component.

---

Q: Does АРИФАМ have any known effects on kidney function over time?

Regulatory information indicates that the diuretic component (Indapamide) may cause a temporary functional increase in blood urea and creatinine when starting treatment. This effect is noted to be a particular concern for patients with pre-existing renal insufficiency. The drug is strictly contraindicated in cases of severe renal failure.

---

Q: Does АРИФАМ interact with common over-the-counter pain medications like ibuprofen?

Official documents advise that taking Nonsteroidal Anti-inflammatory Drugs (NSAIDs) such as ibuprofen may reduce the intended blood pressure-lowering effects of АРИФАМ. The combination of NSAIDs with the diuretic component may also increase the risk of issues affecting kidney function.

---

Q: How long does it typically take for the effects of АРИФАМ on blood pressure to become noticeable?

The full blood pressure-lowering effect may not be immediate after starting the medication. Official data indicates that the therapeutic effect, particularly due to the progressive action of the Indapamide component, may take several weeks or months to reach its maximum benefit.

---

Q: Does the effect of АРИФАМ usually last for a full 24 hours?

The medication is formulated as a modified-release tablet for once-daily administration. This specialized formulation is designed to provide sustained and consistent blood pressure control over a 24-hour period.

---

Q: Is АРИФАМ suitable for older patients, such as those over 65?

Official guidelines state that older adults may be considered eligible for treatment with the fixed combination. However, prescribing information states that the patient's renal (kidney) function must be assessed before and during treatment.

---

Q: Do patients need to be careful about sun exposure while taking АРИФАМ?

Official product information indicates that the Indapamide component may increase the risk of photosensitivity, which is an increased sensitivity of the skin to sunlight or UV light. Regulatory information notes that protection from the sun or artificial UV light is required due to this risk.

---

Q: Is a persistent cough a known side effect of АРИФАМ?

Unlike some other classes of blood pressure medications, a persistent cough is not commonly listed in official adverse event reports for the active ingredients Amlodipine or Indapamide.

---

Q: Does АРИФАМ help with swelling or fluid retention?

The Indapamide component is a diuretic that helps the body reduce circulating fluid volume to lower blood pressure. The combination is formulated to leverage this action and may help counteract the peripheral oedema (swelling) that is a common side effect of the Amlodipine component.

How to Store and Dispose of АРИФАМ

Storage of АРИФАМ (Indapamide/Amlodipine) tablets is strictly defined by regulatory requirements to ensure product stability. The medicine must be stored at a temperature not exceeding 30°C and must be kept from freezing. Protection is required against light and moisture, and the tablets should not be stored in damp locations such as bathrooms.

Packaging and Safety

The product must remain in its original container and the container must be kept tightly closed. As a mandatory safety precaution, the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Official disposal rules prohibit discarding the tablets via wastewater or household waste. Unused or expired medication should be disposed of by consulting a pharmacist or healthcare professional on the proper procedure to help protect the environment.